Rhythm Pharmaceuticals, Inc.

RYTMNASDAQHealthcare● Active

$86.42

+$0.02(+0.02%)

Market Cap$5.9B

P/E Ratio—

52W High$122.2

52W Low$60.7

Avg Volume806K

Open$87.09

Beta1.92

Free Cash Flow Financials Revenue

Rhythm Pharmaceuticals, Inc. (RYTM) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

RYTM · free cash flow · updated Jun 8, 2026

Core FCF metrics

RYTM · FCF · TTM · margin & CAGR

Free cash flow was −$116.6M for FY2025 (fiscal year ending 2025-12-31), down 2.4% year-over-year The FCF margin was -61.5%.

FY2025 Free Cash Flow−$116.6M▼ -2.4% YoY

Trailing 12M (TTM)−$120.5Mtrailing 4 quarters sum

FCF Margin-61.5%−$116.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

RYTM · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$115.7M(1M)−$116.6M▼ 2.4%-61.5%

FY2024−$113.9M(0M)−$113.9M▲ +16.4%-87.5%

FY2023−$136.2M(0M)−$136.2M▲ +23.4%-175.9%

FY2022−$173.4M(4M)−$177.7M▼ 17.3%-751.8%

FY2021−$146.0M(5M)−$151.4M▼ 23.9%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

RYTM · P/FCF · FCF yield · FCF per share

Rhythm Pharmaceuticals, Inc. (RYTM) reported negative free cash flow of −$0.12B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

RYTM · cash flow statement · operating / investing / financing

For FY2025, Rhythm Pharmaceuticals, Inc. generated −$115.7M in operating cash flow and spent 1M in capital expenditures, yielding −$116.6M in free cash flow.

Operating Activities

−$115.7M

Cash from core business operations

2025-12-31

Investing Activities

−$137.2M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$218.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$115.7M) − |CapEx| (1M) = FCF (−$116.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

RYTM vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Rhythm Pharmaceuticals, Inc.YOU

RYTM

−$116.6M-2.4%-61.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Rhythm Pharmaceuticals, Inc. (RYTM) reported free cash flow of −$116.6M for FY2025 (fiscal year ending 2025-12-31), down 2.4% year-over-year. The FCF margin was -61.5%.

Rhythm Pharmaceuticals, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 14 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

RYTM free cash flow · 8 questions

Rhythm Pharmaceuticals, Inc. free cash flow was −$116.6M for FY2025, down 2.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$120.5M.

RYTM free cash flowRYTM FCFRYTM FCF 2025RYTM free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Rhythm Pharmaceuticals, Inc. · Rhythm Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026